5 big analyst AI moves: Microsoft and Amazon downgraded, IBM started at Outperform
CareDx, Inc. (Nasdaq: NASDAQ:CDNA) today announced that the Department of Justice (DOJ) has concluded its investigation into CareDx with no finding of wrongdoing and declined to take any further action.
In a Court document unsealed on October 7, 2024, the DOJ indicated that it is declining to intervene in a qui tam action filed by a former CareDx employee.
Today's decision by the DOJ follows the decision made by the U.S. Securities and Exchange Commission (SEC) in September 2023 to close its investigation and take no action against the Company. The Company believes the closure of the DOJ’s investigation underscores that the underlying allegations, which have now been reviewed by two separate government agencies, were meritless, reinforcing its confidence in the integrity of its operations.
The qui tam complaint, which was filed under seal on February 12, 2021, in the federal district court for the Eastern District of New York, is now unsealed. CareDx will continue to vigorously defend itself should the former employee choose to proceed with this litigation.
Is CDNA a bargain right now?
The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy.
Get the bottom line for CDNA plus thousands of other stocks and find your next hidden gem with massive upside.
Full access now available at 55% off for Black Friday early birds!